DCM
VTVT icon

DAFNA Capital Management’s vTv Therapeutics VTVT Stock Holding History

DAFNA Capital Management’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1,825
Closed -$423K – 93
2016
Q2 		$423K Hold
1,825
– – 0.34% 64
2016
Q1 		$377K Hold
1,825
– – 0.33% 73
2015
Q4 		$497K Sell
1,825
-50
-3% -$14K 0.44% 56
2015
Q3 		$489K Buy
+1,875
New +$653K 0.49% 58

Other funds holding VTVT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
PSC
Piper Sandler & Co Minneapolis, Minnesota $102M AUM 0.13% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

DAFNA Capital Management's VTVT Position: Q3 2016 in Review

DAFNA Capital Management sold out of vTv Therapeutics (VTVT) in Q3 2016, closing a stake of 1,825 shares — an estimated $423K sold.

DAFNA Capital Management first reported a position in VTVT in Q3 2015 and held it in 4 quarters. The position peaked at $497K in Q4 2015. 36 funds tracked by Wall St. Rank hold VTVT as of Q3 2016.

  • DAFNA Capital Management reported no remaining vTv Therapeutics position as of Q3 2016 after selling out during the quarter.
  • DAFNA Capital Management sold 1,825 vTv Therapeutics shares in Q3 2016, an estimated $423K.
  • DAFNA Capital Management first reported a position in vTv Therapeutics in Q3 2015 and held it in 4 quarters.
  • DAFNA Capital Management's vTv Therapeutics position peaked at $497K in Q4 2015.
  • 36 funds tracked by Wall St. Rank held vTv Therapeutics as of Q3 2016.

Based on DAFNA Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.